Clinical Trials Browser

Non-Muscle Invasive Bladder Neoplasms × durvalumab × 90 days × Clear all

NCT05943106 2026-05-26

PATAPSCO

Phase 3 Active not recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT03317158 2026-04-15

ADAPT-BLADDER

Phase 1/2 Recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03528694 2026-04-14

POTOMAC

Phase 3 Active not recruiting

1,018 enrolled 1 FDA

Non-Muscle Invasive Bladder Neoplasms

NCT06503614 2026-04-08

ENHANCE

Phase 2 Recruiting

Non-Muscle Invasive Bladder Neoplasms